MA42624A - Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitive - Google Patents
Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitiveInfo
- Publication number
- MA42624A MA42624A MA042624A MA42624A MA42624A MA 42624 A MA42624 A MA 42624A MA 042624 A MA042624 A MA 042624A MA 42624 A MA42624 A MA 42624A MA 42624 A MA42624 A MA 42624A
- Authority
- MA
- Morocco
- Prior art keywords
- compositions
- treatment methods
- benzodiazepine derivatives
- cognitive deficiency
- cognitive
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562182336P | 2015-06-19 | 2015-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42624A true MA42624A (fr) | 2021-04-28 |
Family
ID=57546444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA042624A MA42624A (fr) | 2015-06-19 | 2016-06-17 | Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitive |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10815242B2 (enExample) |
| EP (1) | EP3310785B1 (enExample) |
| JP (2) | JP6987384B2 (enExample) |
| CN (2) | CN108026107B (enExample) |
| AU (2) | AU2016279052A1 (enExample) |
| CA (1) | CA2990004C (enExample) |
| EA (1) | EA036844B1 (enExample) |
| IL (1) | IL256354B (enExample) |
| MA (1) | MA42624A (enExample) |
| MX (2) | MX392119B (enExample) |
| WO (1) | WO2016205739A1 (enExample) |
| ZA (1) | ZA201800360B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX381561B (es) | 2013-12-20 | 2025-03-12 | Agenebio Inc | Derivados de benzodiazepina, composiciones, y métodos para tratar el deterioro cognitivo. |
| US10815242B2 (en) | 2015-06-19 | 2020-10-27 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US11505555B2 (en) | 2016-12-19 | 2022-11-22 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US20180170941A1 (en) * | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| CA3104478A1 (en) * | 2018-06-19 | 2019-12-26 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| WO2020165802A1 (en) * | 2019-02-13 | 2020-08-20 | Centre For Addiction And Mental Health | Compositions and methods relating to use of agonists of alpha5-containing gabaa receptors |
| MX2022007725A (es) * | 2019-12-19 | 2022-07-19 | Agenebio Inc | Derivados de benzodiazepinas, composiciones y metodos para tratar deterioro cognitivo. |
| IL299761A (en) * | 2020-07-10 | 2023-03-01 | Agenebio Inc | GABAA alpha 5 agonist polymorphs and methods of use for the treatment of cognitive impairment |
| WO2024039886A1 (en) | 2022-08-19 | 2024-02-22 | Agenebio, Inc. | Benzazepine derivatives, compositions, and methods for treating cognitive impairment |
| WO2024196801A1 (en) * | 2023-03-17 | 2024-09-26 | LAPKO INC, dba AFECTA PHARMACEUTICALS | Methods for treating aberrant behavior and motor activity |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3391142A (en) | 1966-02-09 | 1968-07-02 | Lilly Co Eli | Adamantyl secondary amines |
| US3539573A (en) | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| CA974518A (en) | 1972-04-20 | 1975-09-16 | Merz And Co. | Procedure for the manufacture of 1,3,5 trisubstituted adamantan compounds |
| NL7605526A (nl) | 1976-05-24 | 1977-11-28 | Akzo Nv | Nieuwe tetracyclische derivaten. |
| JPS54130587A (en) | 1978-03-30 | 1979-10-09 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
| DE2856393C2 (de) | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
| US4804663A (en) | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| IE58370B1 (en) | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
| GB8607684D0 (en) | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| US4816456A (en) | 1986-10-01 | 1989-03-28 | Summers William K | Administration of monoamine acridines in cholinergic neuronal deficit states |
| HU201906B (en) | 1987-03-04 | 1991-01-28 | Sandoz Ag | Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them |
| FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| US4831031A (en) | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| CA2000786C (en) | 1988-11-07 | 1999-01-26 | Cornelus G. M. Janssen | 3-piperidinyl-1,2-benzisoxazoles |
| US5043345A (en) | 1989-02-22 | 1991-08-27 | Novo Nordisk A/S | Piperidine compounds and their preparation and use |
| DE10299048I2 (de) | 1989-04-14 | 2006-07-13 | Merz Pharma Gmbh & Co Kgaa | Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie |
| ES2076253T3 (es) | 1989-05-19 | 1995-11-01 | Hoechst Roussel Pharma | N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos. |
| US5229382A (en) | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| JP2807577B2 (ja) | 1990-06-15 | 1998-10-08 | エーザイ株式会社 | 環状アミド誘導体 |
| JP2800953B2 (ja) | 1990-07-06 | 1998-09-21 | 住友製薬株式会社 | 新規なイミド誘導体 |
| DE69131268T2 (de) | 1990-09-21 | 1999-12-30 | Rohm And Haas Co., Philadelphia | Dihydropyridazinone und Pyridazinone als Fungizide |
| US5190951A (en) | 1990-10-19 | 1993-03-02 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| WO1992020682A1 (en) | 1991-05-24 | 1992-11-26 | E.I. Du Pont De Nemours And Company | Arthropodicidal anilides |
| US5106856A (en) | 1991-06-07 | 1992-04-21 | Hoechst-Roussel Pharmaceuticals Inc. | [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds |
| TW201311B (enExample) | 1991-06-17 | 1993-03-01 | Hoffmann La Roche | |
| US5312925A (en) | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
| US5763476A (en) | 1994-03-02 | 1998-06-09 | Akzo Noble N.V. | Sublingual or buccal pharmaceutical composition |
| US6479523B1 (en) | 1997-08-26 | 2002-11-12 | Emory University | Pharmacologic drug combination in vagal-induced asystole |
| WO1999025353A1 (en) | 1997-11-13 | 1999-05-27 | Merck Sharp & Dohme Limited | Therapeutic uses of triazolo-pyridazine derivatives |
| US6391922B1 (en) | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| US6294583B1 (en) | 1998-01-13 | 2001-09-25 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders |
| EP1129094A2 (en) | 1998-11-12 | 2001-09-05 | Merck & Co., Inc. | Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same |
| WO2000051985A1 (en) | 1999-03-03 | 2000-09-08 | Eisai Co., Ltd. | Fluorides of 4-substituted piperidine derivatives |
| GB9911803D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| GB9911802D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| GB9911804D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| GB9929569D0 (en) | 1999-12-14 | 2000-02-09 | Merck Sharp & Dohme | Therapeutic agents |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| US20020151591A1 (en) | 2000-10-17 | 2002-10-17 | Anabella Villalobos | Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders |
| TWI239333B (en) | 2000-11-16 | 2005-09-11 | Hoffmann La Roche | Benzodiazepine derivatives as GABA A receptor modulators |
| PA8535601A1 (es) | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
| PL364081A1 (en) | 2001-03-01 | 2004-12-13 | Pfizer Products Inc. | Use of gaba[a] inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders |
| US6686352B2 (en) | 2001-05-18 | 2004-02-03 | Hoffmann-La Roche Inc. | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives |
| AU2002313737A1 (en) | 2001-08-13 | 2003-04-01 | University Of Kentucky Research Foundation | Gene expression profile biomarkers and therapeutic targets for brain aging and age-related cognitive impairment |
| EP1471909A4 (en) | 2002-01-16 | 2007-07-25 | Endo Pharmaceuticals Inc | PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM |
| GB0218876D0 (en) | 2002-08-13 | 2002-09-25 | Merck Sharp & Dohme | Therapeutic agents |
| AU2003246979B8 (en) | 2002-08-13 | 2009-08-06 | Merck Sharp & Dohme Limited | Phenylpyridazine derivatives as ligands for GABA receptors |
| US7635709B2 (en) | 2002-09-26 | 2009-12-22 | The United States Of America As Represented By The Department Of Veterans Affairs | Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction |
| AU2003274353B2 (en) | 2002-10-24 | 2007-04-05 | Merz Pharma Gmbh & Co. Kgaa | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
| CN101249091A (zh) | 2002-11-22 | 2008-08-27 | 约翰斯·霍普金斯大学 | 治疗认知功能障碍的靶位 |
| WO2005079779A1 (en) | 2003-10-22 | 2005-09-01 | Merz Pharma Gmbh & Co. Kgaa | THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC Aß PEPTIDES IN AMYLOIDOPATHIES |
| KR20070046185A (ko) | 2004-09-23 | 2007-05-02 | 메르츠 파마 게엠베하 운트 코. 카가아 | 소아 행동장애의 치료를 위한 메만틴 |
| MX2007004250A (es) * | 2004-10-12 | 2007-06-12 | Hoffmann La Roche | Derivados de imidazo[1,5-a]triazolo[1,5-d]benzodiazepina para el tratamiento de trastornos cognitivos. |
| RU2007112940A (ru) | 2004-10-20 | 2008-11-27 | Ф.Хоффманн-Ля Рош Аг (Ch) | Производные имидазобензодиазепина |
| CA2584757C (en) | 2004-10-20 | 2012-07-03 | F. Hoffmann-La Roche Ag | Halogen substituted benzodiazepine derivatives |
| KR100923393B1 (ko) * | 2004-12-14 | 2009-10-23 | 에프. 호프만-라 로슈 아게 | Ｇａｂａ 수용체 조절제로서 테트라사이클릭이미다조-벤조다이아제핀 |
| US20060205822A1 (en) | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
| EP1888594A2 (en) | 2005-05-16 | 2008-02-20 | Wisys Technology Foundation, Inc. | Gabaergic agents to treat memory deficits |
| US8510055B2 (en) | 2005-08-03 | 2013-08-13 | The Johns Hopkins University | Methods for characterizing and treating cognitive impairment in aging and disease |
| EP1924712B1 (en) | 2005-08-03 | 2018-10-03 | The Johns Hopkins University | Methods for characterizing and treating cognitive impairment in aging and disease |
| ATE477255T1 (de) | 2005-10-11 | 2010-08-15 | Hoffmann La Roche | Imidazobenzdiazepinderivate |
| JP2009513672A (ja) | 2005-10-31 | 2009-04-02 | ブレインセルス，インコーポレイティド | 神経発生のｇａｂａ受容体媒介調節 |
| US8486979B2 (en) | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
| US7943619B2 (en) | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
| EP2318005B1 (en) | 2008-08-01 | 2017-11-01 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
| BRPI0912587A2 (pt) | 2008-09-24 | 2015-07-28 | Du Pont | "composto, composição fungicida e método para o controle de doenças vegetais causadas por patógenos fúngicos de plantas" |
| CA2737452C (en) | 2008-09-25 | 2018-05-22 | Vive Nano Inc. | Methods to produce polymer nanoparticles and formulations of active ingredients |
| WO2010120370A2 (en) | 2009-04-17 | 2010-10-21 | Xenoport, Inc. | Gamma-amino-butyric acid derivatives as gabab receptor ligands |
| CA2786716A1 (en) | 2010-01-11 | 2011-07-14 | Mithridion, Inc. | Compounds and compositions for cognition-enhancement, methods of making, and methods of treating |
| ES2711973T3 (es) | 2010-11-05 | 2019-05-08 | Hoffmann La Roche | Uso de compuestos farmacéuticos activos para el tratamiento de afecciones del sistema nervioso central |
| MX383953B (es) | 2010-11-15 | 2025-03-14 | Agenebio Inc | Derivados de piridazina, composiciones y metodos para tratar deterioro cognitivo. |
| CN103327980A (zh) * | 2010-11-15 | 2013-09-25 | 艾吉因生物股份有限公司 | 用于治疗认知障碍的苯并二吖庚因衍生物、组合物和方法 |
| JPWO2012161133A1 (ja) | 2011-05-20 | 2014-07-31 | 日産化学工業株式会社 | 置換ピリダジン化合物及び農園芸用殺菌剤 |
| US20150374705A1 (en) | 2012-02-14 | 2015-12-31 | Shanghai Institues for Biological Sciences | Substances for treatment or relief of pain |
| AU2013312240A1 (en) | 2012-09-10 | 2015-03-19 | Ophirex Inc. | Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade |
| MX381561B (es) * | 2013-12-20 | 2025-03-12 | Agenebio Inc | Derivados de benzodiazepina, composiciones, y métodos para tratar el deterioro cognitivo. |
| US10815242B2 (en) | 2015-06-19 | 2020-10-27 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US11505555B2 (en) | 2016-12-19 | 2022-11-22 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US20180170941A1 (en) | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| CN108567787A (zh) | 2017-03-10 | 2018-09-25 | 辛衍雪 | 一种治疗慢性阻塞性肺病的药物组合物 |
| CA3104478A1 (en) | 2018-06-19 | 2019-12-26 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
-
2016
- 2016-06-17 US US15/736,697 patent/US10815242B2/en active Active
- 2016-06-17 JP JP2017565726A patent/JP6987384B2/ja active Active
- 2016-06-17 MA MA042624A patent/MA42624A/fr unknown
- 2016-06-17 AU AU2016279052A patent/AU2016279052A1/en not_active Abandoned
- 2016-06-17 EP EP16812577.1A patent/EP3310785B1/en active Active
- 2016-06-17 CN CN201680042224.6A patent/CN108026107B/zh active Active
- 2016-06-17 IL IL256354A patent/IL256354B/en unknown
- 2016-06-17 MX MX2020013374A patent/MX392119B/es unknown
- 2016-06-17 WO PCT/US2016/038224 patent/WO2016205739A1/en not_active Ceased
- 2016-06-17 MX MX2017015752A patent/MX384734B/es unknown
- 2016-06-17 CA CA2990004A patent/CA2990004C/en active Active
- 2016-06-17 EA EA201890090A patent/EA036844B1/ru not_active IP Right Cessation
- 2016-06-17 CN CN202110582826.3A patent/CN113264939A/zh active Pending
-
2018
- 2018-01-18 ZA ZA2018/00360A patent/ZA201800360B/en unknown
-
2020
- 2020-09-22 US US17/028,917 patent/US11312721B2/en active Active
-
2021
- 2021-01-13 AU AU2021200164A patent/AU2021200164B2/en active Active
- 2021-06-24 JP JP2021105189A patent/JP2021152071A/ja not_active Withdrawn
-
2022
- 2022-02-04 US US17/592,679 patent/US12024525B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EA036844B1 (ru) | 2020-12-28 |
| WO2016205739A1 (en) | 2016-12-22 |
| EP3310785A4 (en) | 2018-12-26 |
| IL256354A (en) | 2018-02-28 |
| JP6987384B2 (ja) | 2021-12-22 |
| ZA201800360B (en) | 2023-03-29 |
| CA2990004C (en) | 2024-04-23 |
| MX392119B (es) | 2025-03-11 |
| CN113264939A (zh) | 2021-08-17 |
| CN108026107A (zh) | 2018-05-11 |
| CN108026107B (zh) | 2021-07-30 |
| US20220274996A1 (en) | 2022-09-01 |
| US20210009602A1 (en) | 2021-01-14 |
| MX384734B (es) | 2025-03-14 |
| AU2021200164A1 (en) | 2021-03-18 |
| US12024525B2 (en) | 2024-07-02 |
| NZ739092A (en) | 2024-07-05 |
| CA2990004A1 (en) | 2016-12-22 |
| US11312721B2 (en) | 2022-04-26 |
| EP3310785A1 (en) | 2018-04-25 |
| MX2017015752A (es) | 2018-04-13 |
| JP2018521034A (ja) | 2018-08-02 |
| IL256354B (en) | 2022-09-01 |
| EA201890090A1 (ru) | 2018-09-28 |
| JP2021152071A (ja) | 2021-09-30 |
| MX2020013374A (es) | 2022-05-06 |
| US20190055258A1 (en) | 2019-02-21 |
| HK1254362A1 (zh) | 2019-07-19 |
| AU2021200164B2 (en) | 2022-09-08 |
| US10815242B2 (en) | 2020-10-27 |
| EP3310785B1 (en) | 2024-11-20 |
| AU2016279052A1 (en) | 2018-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA42624A (fr) | Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitive | |
| EP3555100A4 (en) | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | |
| IL264049A (en) | Compounds, preparations and methods for treating the disease | |
| MA45188A (fr) | Oligonucléotides, compositions et méthodes associées | |
| IL264156A (en) | Compounds, preparations and methods for treating the disease | |
| EP3436018A4 (en) | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS AND METHOD FOR TREATING THEREOF | |
| EP3390666A4 (en) | COMPOSITIONS AND METHODS OF TREATING NURSE DISEASES | |
| PL3377516T3 (pl) | Kompozycja do leczenia nowotworu | |
| PL3580211T3 (pl) | 2-heteroarylo-3-okso-2,3-dihydropirydazyno-4-karboksyamidy do leczenia nowotworu | |
| EP3313530A4 (en) | 4,6-PYRIMIDINYLENE DERIVATIVES AND USE THEREOF | |
| EP3679063A4 (en) | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OR PREVENTION OF HER-CONTROLLED DRUG-RESISTANT CANCER | |
| BR112017018413A2 (pt) | tratamento de pancreatite | |
| MA54254A (fr) | Dérivés de benzodiazépine cytotoxique | |
| ZA201605027B (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| LT3390390T (lt) | Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui | |
| PT3265087T (pt) | Método de tratamento com tradipitant | |
| EP3589659A4 (en) | COMPOUNDS AND USES FOR TREATMENT OF CANCER | |
| LT3353177T (lt) | Tricikliniai heterociklai, skirti vėžio gydymui | |
| EP3457851A4 (en) | DERIVATIVES OF SOBETIROM | |
| CL2015000926A1 (es) | Proceso para la elaboración de compuestos para el tratamiento del cancer derivados de azetidin-1-il-metanona y compuestos intermediarios. | |
| EP3630101A4 (en) | METHODS OF TREATMENT OF FIBROTIC DISEASES | |
| LT3377094T (lt) | Susilpninto virulentiškumo bakterijos, skirtos piktybinių solidinių navikų gydymui | |
| EP3500257A4 (en) | KINASE INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | |
| EP3550976A4 (en) | METHOD FOR SYNERGISTIC TREATMENT OF CANCER | |
| EP3686204A4 (en) | THIENODIAZEPIN DERIVATIVES AND THEIR USES |